Product Program year 2024 Source: CMS Open Payments

Acclarent Navwire

Device Rhinology Otology Laryngology Neurosurgery

PDI 20705031242903

Open in the dashboard

General payments

$63,424

585 payments

Research payments

$0

0 payments

Through program year 2024, $63,424 in general payments and $0 in research payments were reported against Acclarent Navwire (Rhinology Otology Laryngology Neurosurgery).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2024 General $9,183 100
2023 General $11,174 152
2022 General $6,348 110
2021 General $36,719 223

Breakdown

Who paid General payments · program years 2021–2024
  1. Acclarent, Inc $63,160 568 payments
  2. Janssen Pharmaceuticals, Inc $154 10 payments
  3. Janssen Biotech, Inc. $110 7 payments
Top recipients General payments · program year 2024
  1. Raj Sindwani Otolaryngology · Cleveland, OH $787 9% · 1 payment
  2. Pablo Recinos Neurological Surgery · Cleveland, OH $787 9% · 1 payment
  3. Satyan Sreenath Otolaryngology · Indianapolis, IN $787 9% · 1 payment
  4. Kibwei McKinney Otolaryngology · Oklahoma City, OK $203 2% · 3 payments
  5. Gregory Varjabedian Otolaryngology · Novi, MI $175 2% · 3 payments

The top 5 of 80 recipients; each share is of general payments naming this product in 2024.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2024
  1. Otolaryngology $6,782 75% · 50 practitioners
  2. Neurological Surgery $787 9% · 1 practitioner
  3. Otolaryngology/Facial Plastic Surgery Otolaryngology $160 2% · 1 practitioner
  4. Otolaryngic Allergy Otolaryngology $160 2% · 1 practitioner
  5. Dermatopathology Dermatology $160 2% · 1 practitioner

The top 5 of 18 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2024
  1. Michigan $2,419 26% · 23 recipients
  2. Ohio $1,604 17% · 4 recipients
  3. Indiana $787 9% · 1 recipient
  4. Tennessee $740 8% · 10 recipients
  5. Texas $589 6% · 4 recipients

The top 5 of 18 states; each share is of general payments naming this product in 2024 where a state was reported.

The top 25 states, free in the app

585 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record